end-stage renal disease
Conditions
Interventions
Donor treatment group:Dexmedetomidine
Recipient Treatment Group:Dexmedetomidine
Whole Process Team:Dexmedetomidine
Sponsors
The First Affiliated Hospital to Sun Yat-Sen University
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: Donors: 1.Patients scheduled for nephrectomy under general anesthesia; 2.Patient aged 18 to 65 years; 3.Able and willing to provide signed informed consent; 4.ASA physical status I-IV. Recipients: 1.Patients receiving living donor kidney transplantation from relatives; 2.Patient aged 18 to 65 years; 3.Able and willing to provide signed informed consent; 4.ASA physical status I-IV.
Exclusion criteria
Exclusion criteria: 1.Patients who are allergic to dexmedetomidine; 2.Patients with advanced heart block; 3.A history of using a2 adrenergic receptor agonist drugs (such as clonidine) within one week before surgery.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Kidney Injury Molecule-1(KIM-1);Neutrophil gelatinase-associated apolipoprotein(NGAL);Serum cystatin C;Liver-fatty acid binding protein(L-FABP); | — |
Secondary
| Measure | Time frame |
|---|---|
| Inflammatory factor IL-6 in the blood;Renin;Serum creatinine value;urine;Kidney ultrasound;Incidence of delayed recovery of transplanted kidney function;Time in hospital after surgery;opioid use during surgery;Urea Nitrogen;Postoperative bleeding;CRRT after surgery;Tumor necrosis factor(TNF-a);The amount of infusion in the operation;Albumin;Hepatocyte growth factor(HGF);Necrosis factor 1;Chemokine 16;Calbindin;Acute rejection;Monocyte chemoattractant protein-1(MCP-1);ß2 microglobulin;Soluble tumor necrosis factor-1;Vascular growth factor;Tissue inhibitor of metalloproteinase 1;Macrophage migration inhibitory factor;Osteoactivin;Trefoil Factor3;Clusterin;Osteopontin; | — |
Countries
China
Contacts
Public ContactWen Shihong
The First Affiliated Hospital to Sun Yat-Sen University
Outcome results
None listed